Recombinant Human Claudin-9/CLDN9 Protein-VLP Protein (HEK293)，His

Claudin-9 (CLDN9) is a member of the claudin family, integral membrane proteins that are crucial components of tight junctions in epithelial and endothelial cells. These proteins play a vital role in maintaining cell polarity, barrier function, and regulating paracellular transport. Given that CLDN9 is involved in various physiological processes and diseases, including cancer and inflammatory disorders, it has garnered significant interest as a potential therapeutic target. Research has shown that CLDN9 is differentially expressed in various tissues and can influence cell migration and proliferation. In recent years, the use of virus-like particles (VLPs) to deliver recombinant proteins has emerged as a promising strategy in vaccine development and therapeutic applications. VLPs can effectively mimic natural viruses, providing an efficient way to present antigens and elicit robust immune responses without the risk of infection. The development of CLDN9 protein VLPs aims to explore their potential as a novel vaccine or therapeutic modality, leveraging the immunogenic properties of VLPs to drive specific immunity against CLDN9-associated pathological conditions. By investigating the structural and functional attributes of CLDN9 within the context of VLPs, researchers aim to establish a foundational understanding that could lead to innovative treatments for diseases where CLDN9 plays a pivotal role. This research could pave the way for therapeutic interventions that specifically target CLDN9 dynamics, enhancing our ability to combat related diseases effectively.